LDL Cholesterol Reduction with Ezetimibe
Ezetimibe 10 mg monotherapy lowers LDL cholesterol by approximately 15-25%, with most high-quality evidence supporting an 18-20% reduction. When added to statin therapy, ezetimibe provides an incremental LDL-C reduction of approximately 20-25% beyond the statin effect alone 1, 2.
Monotherapy Efficacy
- Ezetimibe 10 mg as monotherapy reduces LDL-C by 18% according to FDA prescribing information 1
- Multiple guidelines cite a reduction range of 15-20% for monotherapy 3
- Research evidence supports reductions of 15-25% from baseline when used alone 4, 5
- The drug inhibits intestinal cholesterol absorption by approximately 54%, which translates to these LDL-C reductions 2
Combination Therapy with Statins
When added to statin therapy, ezetimibe provides substantially greater incremental benefit:
- Incremental LDL-C reduction of 25% when combined with statins (placebo-corrected) 1
- In combination with simvastatin 40 mg, the total LDL-C reduction reaches approximately 50% 6
- When added to moderate-intensity statins in post-ACS patients, ezetimibe lowered LDL-C by an additional 17-20 mg/dL regardless of baseline LDL-C levels 7
Specific Clinical Scenarios
In chronic kidney disease patients, ezetimibe 10 mg plus simvastatin 20 mg lowered LDL-C by:
- 37 mg/dL (33%) in non-dialysis patients
- 23% in dialysis patients 6
In homozygous familial hypercholesterolemia, ezetimibe added to high-dose statins (40-80 mg) reduced LDL-C by:
- 21% when pooled across statin doses
- 27% when combined with 80 mg atorvastatin or simvastatin 2
In adolescents with heterozygous familial hypercholesterolemia, ezetimibe plus simvastatin reduced LDL-C by an additional 15% compared to simvastatin alone 2
Alternative Dosing Strategies
- Ezetimibe 5 mg (prescribed as a split 10 mg tablet) produces clinically equivalent LDL-C reduction of approximately 26%, similar to the full 10 mg dose 8
- Thrice-weekly dosing (rather than daily) reduces LDL-C by approximately 20%, which may be useful for patients intolerant of daily dosing 9
- These alternative regimens are supported by ezetimibe's 22-hour elimination half-life 2, 9
Mechanism and Additional Effects
The LDL-C reduction occurs through:
- Inhibition of the NPC1L1 transporter in the small intestine 1, 2
- Decreased hepatic cholesterol stores leading to upregulation of LDL receptors 2
- Increased fractional catabolic rate of apoB-100-containing lipoproteins by approximately 24% 10
Important caveat: While ezetimibe consistently lowers LDL-C levels, the 2013 ACC/AHA guidelines initially noted insufficient data to evaluate its efficacy as monotherapy for cardiovascular outcomes 6. However, the subsequent IMPROVE-IT trial demonstrated that adding ezetimibe to moderate-intensity statins reduced cardiovascular events by 6% relative risk (2% absolute risk) over 7 years, validating that LDL-C lowering with ezetimibe translates to clinical benefit 11, 12.